Adenosine A-2a receptor antagonist enhances clinical response to levodopa in PD

15 June 2008 Print this article Comments Share this article
Istradefylline, a novel and selective adenosine A-2a receptor antagonist, enhances the clinical response to levodopa in patients with Parkinson disease (PD) without substantially increasing dyskinesia, researchers report....

Want to read complete article? Please Sign in or Register.